UNSPSC 51433936: Manidipine hydrochloride

This classification denotes a calcium channel blocker with the molecular structure C35H38N4O6.2CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, ZL507UZ6QL chemically known as 2-(4-(diphenylmethyl)-1-piperazinyl)ethyl methyl (+/-)-1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinecarboxylate dihydrochloride, but more commonly known as manidipine hydrochloride, which bears US NIH Compound Identifier 150762.

UNSPSC 51433936 Manidipine hydrochloride, a Commodity code, represents a single pharmaceutical product line that state and local governments procure primarily through emergency medical services, health department pharmacy programs, and cooperative purchasing agreements rather than as a standalone direct-purchase item. The code designation itself names a specific calcium channel blocker medication, but recent state and local solicitations tagged with this code show broader emergency life support medication procurement, multi-source generic pharmaceutical agreements, and pharmacy benefit program initiatives where manidipine hydrochloride may be included as one line item among dozens in a larger pharmaceutical bundle. State and local issuing bodies—city fire departments, state health agencies, and multi-state cooperative purchasing alliances—are soliciting pharmaceutical products through RFPs, RFIs, and sealed-bid processes that aggregate multiple medications into single contracts rather than individual medication SKUs. The Tampa Fire Rescue procurement exemplifies the operational reality: the city is buying a basket of advanced life support medications (Labetalol, Epinephrine, Adenosine, Diltiazem) as a unit for emergency response, not purchasing manidipine hydrochloride in isolation.

Recent activity shows three primary procurement vehicles. The City of Tampa issued sealed-bid solicitation 26P00188 on April 24, 2026, due April 8, 2026, for advanced life support medications with an estimated contract value of $40,000 and a one-year term plus renewal options, using a Small Local Business Enterprise sheltered-market designation with a 5 percent bid discount. The Texas Health and Human Services Commission issued an RFI on April 3, 2026, exploring direct-to-manufacturer prescription programs for its pharmacy benefit initiative—a market-intelligence phase preceding formal RFP issuance. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP on January 20, 2026, due March 26, 2026, to establish multi-award generic pharmaceutical and OTC contracts across participating states including Oregon, with products available through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson, and a contract term of two years effective July 1, 2026. Geographic activity centers on Florida (Tampa), Texas (HHS), and the Upper Midwest and Pacific Northwest through MMCAP. The code shows procurement activity but little focused demand for manidipine hydrochloride as a distinct line item within recent state and local solicitations; the code may see increased activity as part of larger pharmacy procurement cycles or specialty medication programs that remain in early information-gathering phases.